Phân tích các yếu tố liên quan đến chi phí điều trị suy tim tại Bệnh viện Lê Văn Thịnh

Heart failure (HF) represents a major global health challenge, characterized by its high prevalence, particularly among the elderly, and significant contribution to healthcare burdens. In Vietnam, with its aging demographic and rising non-communicable diseases, HF is a leading cause of hospitalization, imposing substantial treatment costs on both patients and the healthcare system. Understanding these economic implications is crucial for effective healthcare management and financial planning. Existing data often lack detailed cost breakdowns based on specific patient conditions and comorbidities. This study aims to fill this gap by conducting a health economic analysis to identify the key factors associated with the heart failure treatment costs specifically at Le Van Thinh Hospital, providing valuable insights for cost management and policy formulation within the Vietnamese context.

Quản lý bệnh viện, các nhà hoạch định chính sách y tế, nhà kinh tế y tế, chuyên gia y tế (đặc biệt là chuyên khoa tim mạch), và các nhà nghiên cứu quan tâm đến chi phí chăm sóc sức khỏe và quản lý bệnh suy tim.

This study undertook a cross-sectional descriptive study utilizing retrospective data from 2,386 heart failure treatment episodes at Le Van Thinh Hospital in 2024 to elucidate the factors associated with the treatment costs. The methodology involved multivariate linear regression analysis to assess the relationship between total treatment cost (log-transformed) and various independent variables, including patient demographics, type of treatment, length of stay, and specific comorbidities like atrial fibrillation, stent placement, diabetes mellitus, and chronic kidney disease. The findings revealed a sample predominantly consisting of outpatient episodes (93.2%), with an average outpatient cost of 794,000 VND and a median inpatient cost of 5,353,000 VND. Medications constituted a substantial portion of expenses, accounting for 85.8% of outpatient and 37.8% of inpatient costs. Significantly, the regression model, with an R² of 0.847, identified inpatient treatment (+179.4%), stent placement (+16.5%), heart failure with type 2 diabetes (+30.3%), and each additional day of hospitalization (+21.9%) as factors driving higher costs. These results underscore that treatment costs for heart failure are strongly influenced by specific patient health conditions and the intensity of care. The health economic analysis provides a crucial foundation for enhanced financial planning and cost management within hospitals, facilitating informed decision-making for hospital administrators and healthcare policymakers in Vietnam to optimize resource allocation and implement effective cost-control strategies, especially by promoting preventative measures for comorbidities and managing medication expenditures.